title: To PLEX or not to PLEX in natalizumab-associated PML.
authors.affiliation: From the Departments of Neurology (K.L.T., T.L.V.) and Medicine (Infectious Diseases) (K.L.T.), Immunology-Microbiology, University of Colorado School of Medicine, Aurora. ken.tyler@ucdenver.edu.
authors.forename: Kenneth L
authors.initials: KL
authors.lastname: Tyler
authors.affiliation: From the Departments of Neurology (K.L.T., T.L.V.) and Medicine (Infectious Diseases) (K.L.T.), Immunology-Microbiology, University of Colorado School of Medicine, Aurora.
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Vollmer
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000628:therapy*; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab / Q000009:adverse effects*; D010951:Plasma Exchange / Q000379:methods*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab